Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

PaperCitations, authors & open-access status

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 266 citations, 2018 year and hybrid oa status.